Loading...
XSHE
002940
Market cap750mUSD
Jul 10, Last price  
27.11CNY
1D
4.43%
1Q
-12.66%
IPO
55.99%
Name

Zhejiang Anglikang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002940 chart
P/E
42.38
P/S
3.76
EPS
0.64
Div Yield, %
0.87%
Shrs. gr., 5y
1.13%
Rev. gr., 5y
1.88%
Revenues
1.42b
-6.46%
681,508,472773,793,587671,580,995873,154,4131,255,047,6571,396,193,9051,289,647,1011,380,377,6361,568,437,2181,620,569,6491,513,098,0101,415,306,511
Net income
125m
+56.15%
50,127,70364,027,33682,187,659101,085,359108,697,467112,269,991163,719,122119,844,210127,296,300138,372,38880,334,514125,441,397
CFO
246m
-2.87%
50,458,000138,588,381141,744,622193,773,170133,612,108213,493,104198,612,986197,652,364184,746,829276,909,170253,598,389246,331,806
Dividend
Nov 24, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a company primarily focused on the manufacturing and distribution of various pharmaceutical goods. Their operations span the production and sale of active pharmaceutical ingredients (APIs), finished drug formulations, and empty capsules for medical use. The company's existing product line encompasses treatments for a variety of conditions, including anti-infective agents, antihypertensives for blood pressure management, medications for digestive system health, and respiratory preparations. Beyond its current offerings, AngLiKang is also deeply involved in drug research and development. Their R&D efforts are concentrated on creating new therapies, with a particular emphasis on oral cephalosporin antibiotics, as well as treatments for cardiovascular, renal (kidney), and central nervous system diseases. The company was established in 2001 and maintains its headquarters in Shengzhou, China.
IPO date
Oct 23, 2018
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT